CALGB-80405-SIDEDNESS

NCT00265850 📎

Regimen

Experimental
Cetuximab + FOLFOX or FOLFIRI (per investigator choice)
Control
Bevacizumab + FOLFOX or FOLFIRI (per investigator choice)

Population

RAS wild-type (KRAS exon 2) metastatic CRC, 1L; subgroup re-analysis by primary tumor sidedness from the CALGB 80405 trial (subgroup re-analysis: sidedness).

Key finding

Sidedness pooled analysis: Left-sided RAS-wt mCRC: anti-EGFR superior to anti-VEGF (mOS difference ~7 mo); Right-sided RAS-wt: anti-VEGF preferred (anti-EGFR neutral or harmful); Right-sided RAS-wt on anti-EGFR: worse OS than right-sided on anti-VEGF; interaction test significant (p<0.001); provides strongest pooled evidence for sidedness-based biologic selection

Source: PMID 34061178

Timeline

    Guideline citations

    • NCCN Colon (p.140)